메뉴 건너뛰기




Volumn 30, Issue 2, 2010, Pages 212-221

A cost-effectiveness analysis of three treatments for age-related macular degeneration

Author keywords

Age related macular degeneration; Cost effectiveness; Pegaptanib; Photodynamic therapy; Ranabizumab; Treatment

Indexed keywords

PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

EID: 76749111095     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181babd8e     Document Type: Article
Times cited : (23)

References (36)
  • 1
    • 1842530296 scopus 로고    scopus 로고
    • Causes and prevalence of visual impairment among adults in the United States
    • DOI 10.1001/archopht.122.4.477
    • Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485. (Pubitemid 38456282)
    • (2004) Archives of Ophthalmology , vol.122 , Issue.4 , pp. 477-485
    • Congdon, N.1
  • 2
    • 0025776268 scopus 로고
    • Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study
    • Macular Photocoagulation Study Group
    • Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1242-1257.
    • (1991) Arch Ophthalmol , vol.109 , pp. 1242-1257
  • 3
    • 0025837828 scopus 로고
    • Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial
    • Macular Photocoagulation Study Group
    • Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1220-1231.
    • (1991) Arch Ophthalmol , vol.109 , pp. 1220-1231
  • 4
    • 0025887896 scopus 로고
    • Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial
    • Macular Photocoagulation Study Group
    • Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1232-1241.
    • (1991) Arch Ophthalmol , vol.109 , pp. 1232-1241
  • 5
    • 0342632445 scopus 로고    scopus 로고
    • Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Oneyear results of 2 randomized clinical trials-TAP report 1
    • Treatment of age-related macular degeneration with photody- namic therapy (TAP) Study Group
    • Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: oneyear results of 2 randomized clinical trials-TAP report 1. Treatment of age-related macular degeneration with photody- namic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117:1329-1345.
    • (1999) Arch Ophthalmol , vol.117 , pp. 1329-1345
  • 6
    • 11144239923 scopus 로고    scopus 로고
    • Pegaptanib for neovascular age-related macular degeneration
    • VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
    • Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
    • (2004) N Engl J Med , vol.351 , pp. 2805-2816
    • Gragoudas, E.S.1    Adamis, A.P.2    Cunningham Jr., E.T.3    Feinsod, M.4    Guyer, D.R.5
  • 7
    • 33749445317 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • MARINA Study Group
    • Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
    • (2006) N Engl J Med , vol.355 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3
  • 8
    • 33749451356 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    • ANCHOR Study Group
    • Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
    • (2006) N Engl J Med , vol.355 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3
  • 9
    • 26844485888 scopus 로고    scopus 로고
    • The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data
    • Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data. Am J Ophthalmol 2005;140:679-687.
    • (2005) Am J Ophthalmol , vol.140 , pp. 679-687
    • Brown, G.C.1    Brown, M.M.2    Campanella, J.3    Beauchamp, G.R.4
  • 10
    • 44349110000 scopus 로고    scopus 로고
    • A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration
    • Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115:1039 -1045.e5.
    • (2008) Ophthalmology , vol.115 , pp. 1039-1045
    • Brown, M.M.1    Brown, G.C.2    Brown, H.C.3    Peet, J.4
  • 11
    • 36749011885 scopus 로고    scopus 로고
    • Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada
    • Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther 2007; 29:2096-2106.
    • (2007) Clin Ther , vol.29 , pp. 2096-2106
    • Earnshaw, S.R.1    Moride, Y.2    Rochon, S.3
  • 12
    • 48949116261 scopus 로고    scopus 로고
    • Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
    • Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 2008;6:12.
    • (2008) Cost Eff Resour Alloc , vol.6 , pp. 12
    • Hurley, S.F.1    Matthews, J.P.2    Guymer, R.H.3
  • 13
    • 47749151493 scopus 로고    scopus 로고
    • Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity
    • Javitt JC, Zlateva GP, Earnshaw SR, et al. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health 2007;11:563-574.
    • (2007) Value Health , vol.11 , pp. 563-574
    • Javitt, J.C.1    Zlateva, G.P.2    Earnshaw, S.R.3
  • 14
    • 0034759058 scopus 로고    scopus 로고
    • The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration
    • DOI 10.1016/S0161-6420(01)00764-3, PII S0161642001007643
    • Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-2059. (Pubitemid 33032778)
    • (2001) Ophthalmology , vol.108 , Issue.11 , pp. 2051-2059
    • Sharma, S.1    Brown, G.C.2    Brown, M.M.3    Hollands, H.4    Shah, G.K.5
  • 15
    • 34247358129 scopus 로고    scopus 로고
    • Relative cost of a line of vision in age-related macular degeneration
    • Smiddy WE. Relative cost of a line of vision in age-related macular degeneration. Ophthalmology 2007;114:847-854.
    • (2007) Ophthalmology , vol.114 , pp. 847-854
    • Smiddy, W.E.1
  • 17
    • 18844394808 scopus 로고    scopus 로고
    • How to interpret a healthcare economic analysis
    • Brown MM, Brown GC. How to interpret a healthcare economic analysis. Curr Opin Ophthalmol 2005;16:191-194.
    • (2005) Curr Opin Ophthalmol , vol.16 , pp. 191-194
    • Brown, M.M.1    Brown, G.C.2
  • 18
    • 0037314160 scopus 로고    scopus 로고
    • National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10
    • Clemons TE, Chew EY, Bressler SB, McBee W; Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol 2003;121:211-217. (Pubitemid 36184034)
    • (2003) Archives of Ophthalmology , vol.121 , Issue.2 , pp. 211-217
    • Clemons, T.E.1    Chew, E.Y.2    Bressler, S.B.3    McBee, W.4
  • 19
    • 0003951293 scopus 로고    scopus 로고
    • American Academy of Ophthalmology. San Francisco: American Academy of Ophthalmology
    • American Academy of Ophthalmology. Preferred Practice Pattern. Age-Related Macular Degeneration. San Francisco: American Academy of Ophthalmology; 2001.
    • (2001) Preferred Practice Pattern. Age-Related Macular Degeneration
  • 20
    • 16844375997 scopus 로고    scopus 로고
    • Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial
    • Visudyne in Minimally Classic Choroidal Neovascularization Study Group
    • Azab M, Boyer DS, Bressler NM, et al; Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123:448-457.
    • (2005) Arch Ophthalmol , vol.123 , pp. 448-457
    • Azab, M.1    Boyer, D.S.2    Bressler, N.M.3
  • 21
    • 0036145056 scopus 로고    scopus 로고
    • Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2
    • Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002; 133:168-169.
    • (2002) Am J Ophthalmol , vol.133 , pp. 168-169
    • Bressler, N.M.1
  • 22
    • 0036875646 scopus 로고    scopus 로고
    • Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: Additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3
    • Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group
    • Bressler NM, Arnold J, Benchaboune M, et al; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 2002;120:1443-1454.
    • (2002) Arch Ophthalmol , vol.120 , pp. 1443-1454
    • Bressler, N.M.1    Arnold, J.2    Benchaboune, M.3
  • 23
    • 0036305925 scopus 로고    scopus 로고
    • Quality of life with visual acuity loss from diabetic retinopathy and agerelated macular degeneration
    • Brown MM, Brown GC, Sharma S, Landy J, Bakal J. Quality of life with visual acuity loss from diabetic retinopathy and agerelated macular degeneration. Arch Ophthalmol 2002;120:481-484.
    • (2002) Arch Ophthalmol , vol.120 , pp. 481-484
    • Brown, M.M.1    Brown, G.C.2    Sharma, S.3    Landy, J.4    Bakal, J.5
  • 25
    • 1842556553 scopus 로고    scopus 로고
    • Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials-TAP and VIP report No. 3
    • Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy Study Group
    • Arnold JJ, Blinder KJ, Bressler NM, et al; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report No. 3. Am J Ophthalmol 2004;137:683-696.
    • (2004) Am J Ophthalmol , vol.137 , pp. 683-696
    • Arnold, J.J.1    Blinder, K.J.2    Bressler, N.M.3
  • 26
    • 33646948521 scopus 로고    scopus 로고
    • Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials
    • VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group
    • VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001.e6.
    • (2006) Ophthalmology , vol.113 , pp. 992-1001
    • D'Amico, D.J.1    Masonson, H.N.2    Patel, M.3
  • 27
    • 0024523990 scopus 로고
    • Methodology for measuring healthstate preferences-I: Measurement strategies
    • Froberg DG, Kane RL. Methodology for measuring healthstate preferences-I: measurement strategies. J Clin Epidemiol 1989;42:345-354.
    • (1989) J Clin Epidemiol , vol.42 , pp. 345-354
    • Froberg, D.G.1    Kane, R.L.2
  • 28
    • 0024354921 scopus 로고
    • Methodology for measuring healthstate preferences-II: Scaling methods
    • Froberg DG, Kane RL. Methodology for measuring healthstate preferences-II: scaling methods. J Clin Epidemiol 1989; 42:459-471.
    • (1989) J Clin Epidemiol , vol.42 , pp. 459-471
    • Froberg, D.G.1    Kane, R.L.2
  • 29
    • 0024375537 scopus 로고
    • Methodology for measuring healthstate preferences-IV: Progress and a research agenda
    • Froberg DG, Kane RL. Methodology for measuring healthstate preferences-IV: progress and a research agenda. J Clin Epidemiol 1989;42:675-685.
    • (1989) J Clin Epidemiol , vol.42 , pp. 675-685
    • Froberg, D.G.1    Kane, R.L.2
  • 30
    • 0024413278 scopus 로고
    • Methodology for measuring healthstate preferences-III: Population and context effects
    • Froberg DG, Kane RL. Methodology for measuring healthstate preferences-III: population and context effects. J Clin Epidemiol 1989;42:585-592.
    • (1989) J Clin Epidemiol , vol.42 , pp. 585-592
    • Froberg, D.G.1    Kane, R.L.2
  • 31
    • 6344225683 scopus 로고    scopus 로고
    • Value-based medicine: A new paradigm to evaluate treatments for vitreoretinal diseases and other medical interventions
    • Busbee BG, Brown GC, Brown MM. Value-based medicine: a new paradigm to evaluate treatments for vitreoretinal diseases and other medical interventions. Int Ophthalmol Clin 2004;44:155-172.
    • (2004) Int Ophthalmol Clin , vol.44 , pp. 155-172
    • Busbee, B.G.1    Brown, G.C.2    Brown, M.M.3
  • 32
    • 0035124965 scopus 로고    scopus 로고
    • Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-Tap report 2
    • Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group
    • Bressler NM; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-Tap report 2. Arch Ophthalmol 2001;119:198-207.
    • (2001) Arch Ophthalmol , vol.119 , pp. 198-207
    • Bressler, N.M.1
  • 33
    • 57949094834 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
    • ANCHOR Study Group
    • Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57- 65.e5.
    • (2009) Ophthalmology , vol.116 , pp. 57-65
    • Brown, D.M.1    Michels, M.2    Kaiser, P.K.3    Heier, J.S.4    Sy, J.P.5    Ianchulev, T.6
  • 34
    • 38349172455 scopus 로고    scopus 로고
    • Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
    • Regillo C, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
    • (2008) Am J Ophthalmol , vol.145 , pp. 239-248
    • Regillo, C.1    Brown, D.M.2    Abraham, P.3
  • 35
    • 21744452454 scopus 로고    scopus 로고
    • Drug pricing for a novel treatment for wet macular degeneration: Using incremental cost-effectiveness ratios to ensure societal value
    • Sharma S, Bakal J, Sharma SM, Covert D, Shah GK. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005;40:369-377.
    • (2005) Can J Ophthalmol , vol.40 , pp. 369-377
    • Sharma, S.1    Bakal, J.2    Sharma, S.M.3    Covert, D.4    Shah, G.K.5
  • 36
    • 34548355065 scopus 로고    scopus 로고
    • The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials
    • DRCRnet and the SCORE Study Groups
    • Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454-456.
    • (2007) Am J Ophthalmol , vol.144 , pp. 454-456
    • Bhavsar, A.R.1    Ip, M.S.2    Glassman, A.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.